An exploratory analysis of 13,670 patients across SUSTAIN 6, PIONEER 6, and LEADER found that semaglutide and liraglutide treatment effects varied little by baseline patient factors, with baseline hemoglobin A1c ranking highest as an effect modifier but explaining only a small amount of heterogeneity. In other words: for most of the patients you manage on the front lines, the average treatment effect was a reasonable guide across A1c, BMI, and blood pressure outcomes.

Why It Matters To Your Practice

• NPs and PAs are often the clinicians making real-world diabetes treatment calls, and this study reinforces that your patient-by-patient judgment does not need to be paralyzed by fear of major hidden response differences.

• The analysis focused on treatment effect heterogeneity in GLP-1 receptor agonists for type 2 diabetes, using data from major trials of subcutaneous semaglutide, oral semaglutide, and subcutaneous liraglutide.

• Baseline hemoglobin A1c was the most important candidate effect modifier, with kidney function also ranking relatively high, but the overall magnitude of covariate-driven variation was small.

Clinical Benefits

• The big picture: semaglutide and liraglutide benefits appeared broadly consistent, which supports confident frontline prescribing and follow-up workflows.

• Endpoints included hemoglobin A1c, body mass index, and blood pressure — practical measures you track every day in clinic.

• Because large covariate-driven heterogeneity could be ruled out in these trials, average treatment effects are likely useful for most patients rather than only for narrow subgroups.

Managing Risks

• This was an exploratory analysis, so it helps with clinical framing but does not eliminate the need for individualized monitoring.

• Higher baseline A1c and kidney function may still matter when setting expectations, even if they do not create large differences in treatment response.

• Continue standard vigilance around tolerability, adherence, follow-up labs, weight trends, blood pressure, and glycemic response — the study does not argue against tailored care.

The Bottom Line

• Your role is not secondary here: NPs and PAs are exactly the clinicians who translate trial evidence into day-to-day diabetes wins.

• This analysis suggests semaglutide and liraglutide effects were broadly stable across common baseline characteristics, making the average treatment effect a practical summary for most patients with type 2 diabetes.

• That means you can move decisively: personalize when needed, but do not assume major hidden heterogeneity unless the individual clinical picture gives you a reason.

Reference: Exploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetes